Information Provided By: 
Fly News Breaks for April 19, 2017
TXMD
Apr 19, 2017 | 07:23 EDT
Oppenheimer analyst Jay Olson notes that TherapeuticsMD's shares have declined by 40% since April 7, when the company received a letter from the FDA stating there were deficiencies in the NDA for TX-004HR. The analyst believes this sharp decline in its share price is an overreaction to unspecified NDA deficiencies that he views as likely due to technical aspects of the CMC section. Olson reiterates an Outperform rating and $15 price target on the shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
